Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation - Additional Information (Details)

v3.21.1
Basis of Presentation - Additional Information (Details)
1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended
Feb. 10, 2021
USD ($)
$ / shares
shares
Feb. 09, 2021
USD ($)
$ / shares
shares
Feb. 08, 2021
$ / shares
shares
Feb. 03, 2021
$ / shares
shares
Nov. 02, 2020
USD ($)
$ / shares
shares
Oct. 31, 2020
$ / shares
shares
Oct. 27, 2020
USD ($)
$ / shares
shares
Jul. 02, 2020
$ / shares
shares
Jun. 05, 2020
$ / shares
shares
Jun. 03, 2020
USD ($)
$ / shares
shares
Apr. 30, 2020
USD ($)
Jan. 21, 2020
USD ($)
Debtinstrument
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Nov. 30, 2020
USD ($)
Oct. 31, 2020
$ / shares
shares
Jun. 30, 2020
USD ($)
$ / shares
shares
Mar. 31, 2021
USD ($)
$ / shares
shares
Mar. 31, 2021
USD ($)
$ / shares
shares
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
$ / shares
shares
Jan. 28, 2021
$ / shares
Sep. 08, 2020
USD ($)
Jun. 10, 2020
$ / shares
Jul. 16, 2019
USD ($)
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Description of deferring payment on US payroll taxes                                   In April 2020, the Company began deferring payment on its share of U.S. payroll taxes owed, as allowed by the Coronavirus Aid, Relief and Economic Security Act (CARES Act) through December 31, 2020. The Company is able to defer half of its share of U.S. payroll taxes owed until December 31, 2021, with the remaining half due on December 31, 2022.            
Ordinary shares, shares issued | shares                         49,431,028       179,137,432 179,137,432   49,431,028        
Ordinary shares, par value | $ / shares                         $ 0.01       $ 0.01 $ 0.01   $ 0.01 $ 0.01   $ 0.01  
Net losses                                   $ 98,921,000 $ 16,100,000 $ 52,006,000        
Accumulated deficit                         $ 286,929,000       $ 385,850,000 385,850,000   286,929,000        
Cash and cash equivalents                         14,508,000       66,640,000 66,640,000   14,508,000        
Short-term investments                                 $ 33,868,000 $ 33,868,000            
June 3 SPA                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Ordinary shares, par value | $ / shares                                 $ 0.01 $ 0.01            
June 30 SPA                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Ordinary shares, par value | $ / shares                                 $ 0.01 $ 0.01            
February SPA                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Ordinary shares, shares issued | shares   17,500,000                                            
Ordinary shares, par value | $ / shares   $ 0.01                                            
Offering price per share | $ / shares   $ 2.00                                            
Aggregate gross proceeds from ordinary shares   $ 35,000,000                                            
Proceeds from registered direct offerings, net of transaction costs   $ 32,200,000                                            
Percentage of ordinary shares issued to purchase warrants   7.00%                                            
Offering closing date   Feb. 12, 2021                                            
February SPA | Warrant                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Number of warrants to purchase ordinary shares | shares   1,225,000                                            
Warrants to purchase ordinary shares, exercise price | $ / shares   $ 2.50                                            
Warrants expiry date   Feb. 09, 2026                                            
Iterum Therapeutics US Limited | Silicon Valley Bank (SVB) | Paycheck Protection Program                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Aggregate principal amount                     $ 744,000                          
Debt instrument interest rate                     1.00%                          
Debt instrument maturity period                     2 years                          
Debt instrument, description                     Under the terms of the agreement, there shall be no payments due by the Company until the SBA remits the forgiveness amount to the borrower or 10 months after the end of the six-month period beginning April 30, 2020 (the Deferral Period). Following the Deferral Period, equal monthly repayments of principal and interest will be due to fully amortize the principal amount outstanding on the PPP loan by the maturity date.             Under the terms of the agreement, there shall be no payments due by the Company until after the Deferral Period. Following the Deferral Period, equal monthly repayments of principal and interest will be due to fully amortize the principal amount outstanding on the PPP loan by the maturity date.            
Debt instrument, forgiveness loan                           $ 340,000                    
Debt instrument, remaining amount amortized                         404,000         $ 404,000            
Debt Instrument, equal monthly repayments                         $ 26,000         26,000            
Maximum                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Aggregate initial offering price of securities authorized to issue                                               $ 150,000,000
2025 Exchangeable Notes                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Aggregate principal amount                                 $ 14,300,000 $ 14,300,000            
Private Placement and Rights Offering | 2025 Exchangeable Notes                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Aggregate principal amount                       $ 51,800,000                        
Debt instrument interest rate                       6.50%                        
Private Placement and Rights Offering | RLNs                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Aggregate principal amount                       $ 100,000                        
Private Placement | June 3 SPA                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Number of warrants to purchase ordinary shares | shares                 208,023                              
Warrants to purchase ordinary shares, exercise price | $ / shares                 $ 2.1031 $ 1.62                            
Warrants expiry date                 Jun. 03, 2025 Dec. 05, 2025                            
Warrants closing date                   Jun. 05, 2020                            
Percentage of ordinary shares issued to purchase warrants                 7.00%                              
Private Placement | June 30 SPA                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Number of warrants to purchase ordinary shares | shares               236,088                                
Warrants to purchase ordinary shares, exercise price | $ / shares               $ 1.8531               $ 1.42                
Warrants expiry date               Jun. 30, 2025               Jan. 02, 2026                
Warrants closing date                               Jul. 02, 2020                
Percentage of ordinary shares issued to purchase warrants               7.00%                                
Private Placement | Maximum | June 3 SPA                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Number of warrants to purchase ordinary shares | shares                   1,485,885                            
Private Placement | Maximum | June 30 SPA                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Number of warrants to purchase ordinary shares | shares                               1,686,343                
Private Placement | 2025 Exchangeable Notes                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Aggregate principal amount                       51,600,000                        
Debt instrument price per unit                       1,000                        
Private Placement | RLNs                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Aggregate principal amount                       $ 100,000                        
Number of debt instruments within each notes | Debtinstrument                       50                        
Debt instrument, aggregate potential payment capped rate                       4,000 times                        
Private Placement | Securities                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Debt instrument, shares embedded within each unit, shares | shares         1,286.1845             1,000                        
Debt instrument, shares embedded within each unit, value         $ 1,000             $ 1,000                        
Rights Offering in Connection with Private Placement                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Maximum subscription units to be accepted | shares                       220                        
Rights Offering in Connection with Private Placement | 2025 Exchangeable Notes                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Aggregate principal amount                       $ 14,300,000                   $ 200,000    
Debt instrument price per unit                       1,000                        
Debt instrument price per unit                       $ 1,000                        
Debt instrument, shares embedded within each unit, shares | shares         1,286.1845             1,000         51,499,567              
Debt instrument, shares embedded within each unit, value         $ 1,000             $ 1,000                        
Debt instrument, shares embedded within each unit, exchange price | $ / shares         $ 0.7775             $ 1.00                        
Aggregate principal amount of exchangeable notes                                 $ 37,500,000              
Rights Offering in Connection with Private Placement | RLNs                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Aggregate principal amount                                           $ 20,000    
Number of debt instruments within each notes | Debtinstrument                       50                        
Aggregate amount payable per unit                       $ 160.00                        
Debt instrument, aggregate potential payment capped rate                       4,000 times                        
Rights Offering in Connection with Private Placement | RLNs | Minimum                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Debt instrument, percentage of net revenue from domestic sale for potential aggregate payments                       15.00%                        
Rights Offering in Connection with Private Placement | RLNs | Maximum                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Debt instrument, percentage of net revenue from domestic sale for potential aggregate payments                       20.00%                        
Rights Offering in Connection with Private Placement | Securities                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Proceeds from sale of securities                       $ 45,000,000                        
Direct Offering | June 3 SPA                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Ordinary shares, shares issued | shares                   2,971,770                            
Ordinary shares, par value | $ / shares                   $ 0.01                            
Offering price per share | $ / shares                   $ 1.6825                            
Aggregate gross proceeds from ordinary shares                   $ 5,000,000                            
Proceeds from registered direct offerings, net of transaction costs                   $ 4,300,000                            
Direct Offering | June 30 SPA                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Ordinary shares, shares issued | shares                               3,372,686                
Ordinary shares, par value | $ / shares                               $ 0.01                
Offering price per share | $ / shares                               $ 1.4825                
Aggregate gross proceeds from ordinary shares                               $ 5,000,000                
Proceeds from registered direct offerings, net of transaction costs                               $ 4,200,000                
October Offering                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Ordinary shares, shares issued | shares             15,511,537                                  
Ordinary shares, par value | $ / shares             $ 0.01                   $ 0.01 $ 0.01            
Aggregate gross proceeds from ordinary shares             $ 17,400,000                                  
Proceeds from registered direct offerings, net of transaction costs             $ 15,500,000                     $ 13,400,000            
Number of warrants to purchase ordinary shares | shares           1,884,615                 1,884,615   20,232,439 20,232,439            
Warrants to purchase ordinary shares, exercise price | $ / shares           $ 0.8125 $ 0.65               $ 0.8125                  
Warrants expiry date           Oct. 22, 2025 Oct. 27, 2025                                  
Percentage of ordinary shares issued to purchase warrants           7.00%                                    
October Offering | Pre-Funded Warrants                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Offering price per share | $ / shares             $ 0.01                                  
Proceeds from registered direct offerings, net of transaction costs                                       $ 110,000        
Number of warrants to purchase ordinary shares | shares             11,411,539                                  
Warrants to purchase ordinary shares, exercise price | $ / shares             $ 0.64                                  
Percentage of ordinary share at election of purchaser             9.99%                                  
October Offering | Warrant                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Offering price per share | $ / shares             $ 0.65                                  
Number of warrants to purchase ordinary shares | shares             20,192,307                                  
Warrants to purchase ordinary shares, exercise price | $ / shares             $ 0.65                                  
October Offering | Purchase Agreement                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Number of warrants to purchase ordinary shares | shares           1,884,615                 1,884,615                  
Warrants to purchase ordinary shares, exercise price | $ / shares           $ 0.8125                 $ 0.8125                  
Warrants expiry date                             Oct. 22, 2025                  
Percentage of ordinary shares issued to purchase warrants                             7.00%                  
Description of purchase agreement                                   In connection with the October Offering, the Company entered into a Securities Purchase Agreement (the Purchase Agreement) on October 22, 2020 with certain institutional investors. The Purchase Agreement contains customary representations and warranties of the Company, termination rights of the parties, and certain indemnification obligations of the Company and ongoing covenants of the Company, including a prohibition on the Company entering into variable rate transactions for a period of 12 months after the closing of the October Offering, subject to certain exceptions.            
October Offering | Minimum | Pre-Funded Warrants                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Percentage of beneficial ownership that certain purchasers didn't want to exceed             4.99%                                  
October Offering | Maximum                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Number of warrants to purchase ordinary shares | shares             20,192,307                                  
February Underwritten Offering                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Warrants to purchase ordinary shares, exercise price | $ / shares $ 1.4375   $ 1.4375                                          
Warrants expiry date Feb. 03, 2026   Feb. 03, 2026                                          
Percentage of ordinary shares issued to purchase warrants 7.00%   7.00%                                          
Offering closing date Feb. 10, 2021   Feb. 08, 2021                                          
Additional ordinary shares that can be purchased by underwriter | shares 5,217,391                                              
February Underwritten Offering | Underwriting Agreement                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Ordinary shares, shares issued | shares       34,782,609                                        
Ordinary shares, par value | $ / shares       $ 0.01                                        
Offering price per share | $ / shares       $ 1.15                                        
Offering closing date       Feb. 08, 2021                                        
February Underwritten Offering | Pursuant to the Underwriting Agreement                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Ordinary shares, shares issued | shares 40,000,000                                              
Aggregate gross proceeds from ordinary shares $ 46,000,000                                              
Proceeds from registered direct offerings, net of transaction costs $ 42,100,000                                              
Percentage of ordinary shares issued to purchase warrants 7.00%                                              
Additional ordinary shares that can be purchased by underwriter | shares 5,217,391                                              
February Underwritten Offering | Pursuant to the Underwriting Agreement | Warrant                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Number of warrants to purchase ordinary shares | shares 2,800,000                                              
Warrants to purchase ordinary shares, exercise price | $ / shares $ 1.4375                                              
Warrants expiry date Feb. 03, 2026                                              
February Underwritten Offering | Maximum                                                
Organization Consolidation And Presentation Of Financial Statements [Line Items]                                                
Number of warrants to purchase ordinary shares | shares 365,217   2,434,783